FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This project consists of two independent, following specific eligibility criteria and
different randomisation schemes studies, later on called DURATION study and BEV study. Once
randomised in the duration study, patients fulfilling eligibility criteria for BEV study may
also be randomized to receive BEV or no BEV, in addition to FOLFOX-4 chemotherapy.
As both are open label studies, there will be no blinding of treatment assignment.
Phase:
Phase 3
Details
Lead Sponsor:
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Collaborator:
Mario Negri Institute for Pharmacological Research